Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + epirubicin + ifosfamide
- Development stage
- Unknown
- Lead developer
- Johnson Matthey
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Carboplatin + epirubicin + ifosfamide is a combination chemotherapy regimen investigated for the treatment of various malignancies, including small-cell lung cancer (SCLC) and high-risk or metastatic breast cancer. The regimen consists of three small molecule cytotoxic agents: carboplatin, a platinum-based compound that forms DNA cross-links; epirubicin, an anthracycline that inhibits DNA topoisomerase II and intercalates into DNA; and ifosfamide, an alkylating agent that causes DNA strand breaks. In clinical research, this combination has been evaluated both as a standard-dose therapy and as part of high-dose chemotherapy (HDC) protocols supported by autologous peripheral blood stem cell transplantation (PBSCT). While the acronym "ICE" is frequently used for a different regimen containing etoposide, it has been applied to this specific triplet in certain clinical studies.
- Other names
- ICEifosfamide, carboplatin and epirubicintandem HDC
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on carboplatin + epirubicin + ifosfamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + epirubicin + ifosfamide.